Table 2 Univariate analysis of variables in the cycles with one or more oocytes retrieved and zero oocytes retrieved

No. of cycles/all cycles (%)

706/744 (94.9)

38/744 (5.1)

–

Age, years

37 (23–46)^a

39 (31–46)^a

0.01

Gravida per patient, n

0 (0–7)^a

0 (0–6)^a

0.25

Parity per patient, n

0 (0–3)^a

0 (0–4)^a

0.02

BMI, kg/m²

21 (16–36)^a

21 (18–31)^a

0.42

Infertility period, years

6 (0–18)^a

7 (0–16)^a

0.09

Previous treatment cycles, n

2 (1–16)^a

2 (1–14)^a

0.87

No. of cycles with GnRH agonist long/no. of cycles (%)

190/706 (69.4)

19/38 (50.0)

0.02

No. of cycles with GnRH antagonist/no. of cycles/ (%)

216/706 (30.6)

19/38 (50.0)

0.02

Duration of hMG/rFSH, days

11 (7–21)^a

12 (8–20)^a

0.49

Dose of hMG/rFSH, IU

1425 (150–4800)^a

1500 (900–4800)^a

0.20

Hormone levels^b

 FSH, mIU/ml

13.4 (3.2–113.5)^a

16.8 (7.5–43.5)^a

<0.001

 LH, mIU/ml

2.3 (0.1–26.8)^a

3.8 (0.1–45.3)^a

0.006

 PRL, ng/ml

30.7 (0.6–314)^a

21.3 (9.3–56.8)^a

<0.001

 Estradiol, pg/ml

1717 (88–15,768)^a

633 (62–1970)^a

<0.001

 Progesterone, ng/ml

0.77 (0.05–10.9)^a

0.51 (0.1–6.48)^a

0.02

Endometrial thickness^b, mm

10.9 (4.6–21.2)^a

10.3 (6.2–17.2)^a

0.51

No. of follicles over 15.5 mm^b, n

4 (1–16)^a

2 (1–6)^a

<0.001